U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. About FDA
  3. FDA Organization
  4. Office of Inspections and Investigations
  5. OII Inspectorates
  6. Office of Bioresearch Monitoring Inspectorate (OBMI)
  1. OII Inspectorates

Office of Bioresearch Monitoring Inspectorate (OBMI)

The Office of Bioresearch Monitoring Inspectorate (OBMI), within the Office of Inspections and Investigations (OII), is responsible for conducting inspections of clinical and nonclinical research conducted in support of marketing applications for FDA regulated products across all centers. 

OBMI inspections focus on:

  • Ensuring the protection of trial participants involved in clinical research
  • Studies are conducted according to applicable regulations 
  • The reliability of data submitted in applications to FDA 

The OBMI program includes Postmarketing Adverse Drug Experience (PADE) and Risk Evaluation and Mitigation Strategies (REMS) inspections as part of the portfolio.

OBMI's Mission 

OBMI's highly skilled, collaborative, and agile workforce ensures research subjects are protected and the data used to support FDA decisions is reliable.

What We Do

  • Domestic and foreign inspections of regulated entities conducting clinical and nonclinical research
  • Inspections of drug establishments for compliance with PADE and REMS requirements
  • Training and outreach to industry and academia
  • Collaboration with international regulatory partners

Who We Are 

Accomplishments 

Report a Problem

Additional Resources  



Back to Top